Orchid Pharma share price hits 5% upper circuit; stock jumps 24% in 1 week

The inspection, which commenced on February 10, 2025, and concluded on February 18, 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility. This successful inspection maintains Orchid Pharma's distinguished position as India's only USFDA-approved facility for Sterile Cephalosporins. It reaffirms Orchid Pharma's compliance with USFDA regulatory standards, reinforcing the company's commitment to quality and excellence in pharmaceutical manufacturing, the company said.

"The Alathur facility specialises in the production of Cephalosporin antibiotics, a critical class of life-saving drugs. Orchid Pharma remains committed to maintaining the highest standards in pharmaceutical manufacturing to ensure continuous supply to the US and global markets," the filing added.

About Orchid Pharma Limited

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing, and marketing.

In September 2024, Orchid Pharma announced that its newly formed antimicrobial solutions division, Orchid AMS, is targeting a turnover of up to ₹300 crore in the next three years with about 250 strong salespeople onboard while combating the challenge of antimicrobial resistance in India.

Orchid AMS (Antimicrobial Solutions) is targeting to partner with around 2,500-3,000 hospitals and healthcare institutions in the next two to three years to implement effective antimicrobial stewardship programmes (AMSPs).

Antimicrobial resistance is one of the biggest healthcare challenges beyond the hospitals, as medications are available easily without prescriptions, and antibiotics are also coming in through poultry, fish, and crops, Rajnish Rohatgi, CEO, of Orchid AMS, a division of Orchid Pharma, told PTI.

Orchid Pharma share price trend

Shares of Orchid Pharma have rallied nearly 24% in the past 7 sessions, per BSE data. In comparison, the benchmark S&P BSE SENSEX has fallen over 1.7%, while the BSE Healthcare index has slipped 1.83% during the window.